Neil Shastri-Hurst MP: speeches

Speeches

• 30 Jun 2026 · Defence Investment Plan · Hansard source

  More

  In response to the DIP, the noble Lord Hutton, a former Labour Defence Secretary, said that “the centres of resistance across Whitehall to extra defence spending have been allowed to prosper and they haven’t been overcome.” He went on to say that, as a consequence, our armed forces will not be war-ready by the end of this Parliament. Does the Defence Secretary disagree with the noble Lord? How do the £10.7 billion in cuts to the MOD budget enhance our armed forces’ readiness?

• 29 Jun 2026 · Topical Questions · Hansard source

  More

  There are now over 1 million young people not in education, employment or training, which is the highest number in more than a decade. When the history books are written on this period of Government, does the Secretary of State agree that the story will be of a lost generation?

• 25 Jun 2026 · Topical Questions · Hansard source

  More

  T2. Indeed—I am back by popular demand.Will the Minister set out what steps the Cabinet Office is taking to ensure that public appointments are made on merit alone and not based on political patronage or ideological principles?

• 25 Jun 2026 · National Resilience Planning · Hansard source

  More

  9. What steps his Department is taking to improve cross-Government co-ordination on national resilience planning.

• 25 Jun 2026 · National Resilience Planning · Hansard source

  More

  Space has a crucial role to play in our national resilience. Responsibility for it cuts across Government Departments. With that in mind, and given the Cabinet Office’s role in cross-Government co-ordination, can the Minister confirm when the National Space Council will next convene?

• 25 Jun 2026 · Sudan · Hansard source

  More

  This brutal conflict has resulted in more than 14 million people being displaced. Around 5 million of those have been displaced over the border, but 9 million are displaced in Sudan itself. Will the Minister set out what practical steps the Government are taking to support those who are displaced internally?

• 25 Jun 2026 · Neuropsychiatric Conditions: PANS and PANDAS · Hansard source

  More

  It is a privilege to respond to the debate on behalf of His Majesty’s loyal Opposition. I pay tribute to the hon. Member for North East Fife (Wendy Chamberlain) for securing the debate and for setting out the landscape facing those with PANS/PANDAS in the UK, as well as recognising the lack of knowledge about the conditions and the challenge that presents. I thank her for her sustained work through the APPG on the issue. Many right hon. and hon. Members have contributed to the debate. The hon. Member for Carlisle (Ms Minns) spoke movingly about Joanne and Jake, who have been living with PANS/PANDAS for the past six years, and the challenges of not getting the treatment or the funding that they need. The hon. Member for Henley and Thame (Freddie van Mierlo) made a good point about how those affected do not want sympathy but action. He talked about the excellent campaigning by Albie, who is in the Gallery today, following his brother’s diagnosis—I suspect Albie’s handwriting is somewhat better than my doctor’s scrawl and I commend him on his campaigning. The hon. Member for Harlow (Chris Vince), who is always keen to speak up and champion issues on behalf of his constituents, spoke about the importance of guidance. My right hon. Friend the Member for New Forest East (Sir Julian Lewis) talked about the importance of the early use of antibiotics. Above all, I want to speak directly to the families and children who are following the debate and who live with PANS/PANDAS every day, some of whom are with us in the Gallery today. For them, this is not an abstract discussion about guidance, systems or clinical pathways; it is about the child they love, the moment something changed and the exhaustion of trying to explain that change to people who may never have heard of the condition before. It is about parents who overnight become advocates, researchers, case managers and campaigners, while simultaneously trying to hold their families together, and about the children and young people whose lives can be altered suddenly and terrifyingly. As we have heard, PANS/PANDAS sit at the intersection of neurology, psychiatry, immunology and infectious diseases. That matters because they do not fit neatly into one service, specialty, clinic or budget line. For the children affected, symptoms can be sudden and severe. They include obsessive-compulsive behaviours, restricted eating, tics, anxiety, behavioural change, sleep disturbance, regression, movement difficulties, school refusal and distress that can overwhelm the entire family. For some families, the story is stark. A child who was settled and sociable becomes frightened, withdrawn and unable to eat. A child who was thriving at school begins to struggle. Families find themselves moving from GPs to child and adolescent mental health services, from paediatrics to emergency departments, and from school meetings to safeguarding conversations, often without a clear pathway or a clinician who is able to say, “Do you know what? I recognise this, and this is what we need to do next.” The first task before us is to diagnose the problem honestly. The problem is not that every scientific question has been answered, because clearly it has not. There is uncertainty and professional disagreement, and there is a need for stronger evidence, better data and more research into diagnosis, treatment and long-term outcomes. However, uncertainty has too often translated into inconsistency. It has meant too many families left without a clear answer, too many clinicians left without guidance, too many schools unsure of how to respond and too many children caught between services. Each see part of the picture, but they do not see the child as a whole. At present, there is no official NHS clinical guidance for the diagnosis and treatment of PANS/PANDAS. NICE has previously concluded that the evidence was insufficient to provide useful guidance. The Government have said that data on the number of children affected is not currently collected, because internationally the criteria cannot be agreed. Local integrated care systems are expected to plan services, but they are asked to do so without consistent national direction, which risks variation. As we have heard, in reality variation leads to a postcode lottery. It means that one family may find an informed GP, paediatrician or neurologist, while another family is left scrambling for help. It means that one school may understand the sudden onset and fluctuating need, while another school sees only challenging behaviour. It means that one parent may feel believed, while another parent feels blamed. That is the difficulty at the heart of this debate. PANS/PANDAS cut across the way our systems are organised. The NHS is still too often structured around separate silos, whether it is mental health, neurology, infectious disease, immunology or paediatrics, but children living with these conditions do not arrive in neat administrative categories; their needs are complex, sudden and overlapping. That makes it hard for families to know where to turn, as well as for clinicians who want to help but may not have had the training to do so, and for schools that see a child’s behaviour change dramatically without understanding what is driving it. We must also be candid about the emotional difficulty. Parents can feel dismissed. They can feel treated as difficult or seen as overanxious when they are simply trying to explain what has happened to their child. No child should be left waiting for help because the system is unsure about where they fit. The previous Government did not solve this issue, but foundations were laid through the UK rare diseases framework, annual action plans and engagement with research, including with the APPG and the working group. The current Government have welcomed clinical guidance being developed by PANS PANDAS UK and have said that NICE will consider national guidance as evidence improves. They have also pointed to NIHR research and extended the rare diseases framework into 2027. Where the Government do the right thing, we should welcome it, but the question is whether those actions are sufficient. Do they need to go faster? Are they reaching the families on the ground? Families do not experience this as a framework, action plan or written answer; they experience it as the moment when a child refuses food, compulsions appear, school attendance collapses or a parent is told that a professional has never heard of the condition. If the problem is complexity, inconsistency and a lack of recognition, the solution must be equal in its seriousness. The foundations have been set, and now we must all go further. We need action on guidance. The clinical guidance being developed by PANS PANDAS UK and the PANS guideline development group brings together expertise from general practice, paediatrics, neurology, immunology, infectious diseases, psychiatry, psychology and nursing. I would be grateful if the Minister could set out how the Government will engage with that guidance once it is published. Will she commit to a clear process for assessing emerging evidence? We also need to take action on professional awareness. I recall reading about these conditions in Kumar & Clark when I was a medical student, but I do not recall receiving any formal training on them. It is not enough to ask our clinicians to be responsible for keeping their knowledge up to date; atypical, complex and contested conditions require practical support. As such, I ask the Minister to consider an awareness package for frontline professionals, developed in conjunction with clinicians, families and experts. We also need action on data and research—we need better data, diagnostic clarity, and research into treatment and long-term outcomes. With that in mind, I would appreciate the Minister setting out how the Government intend to support that work and encourage greater patient involvement. There is also a need for greater consistency across local systems. If support is left entirely to local discretion, care will depend on where a family lives or how hard they are able to fight for it. Clearer information on how suspected cases can be supported across specialties should be available to ICBs, and schools also have to be part of the answer. For many families, school is where the change is first noticed; better awareness of sudden onset and fluctuating symptoms could help ensure sensible attendance policies and flexible, rapid and responsive classroom adjustments. This debate should not be one that divides the House, but one that unites it. There will be different views on the evidence, on treatment and on guidance, but there should be no difference between us on the need for children to be seen, for families to be heard, for clinicians to be supported, and for care to be based on evidence, rather than the accident of geography. For families living with PANS/PANDAS, progress will be measured by whether the next family gets an earlier answer, whether the next child is believed sooner, whether the next GP has somewhere to turn, and whether the next school understands. That is a fair and compassionate standard, and it is the one that the Government should now meet.

• 22 Jun 2026 · Armed Forces Bill · Hansard source

  More

  I place on record that, as a veteran myself, it was a huge privilege to serve on the Select Committee that considered this important legislation. I will concentrate my remarks on new clauses 4, 9 and 11. At first glance, they may appear to concern different matters, yet, in reality, they are united by the common principle that Parliament should ensure that those who serve this country are treated fairly, and that the law recognises the unique obligations we place on them. We quite rightly celebrate the professionalism of our armed forces. We ask them to defend our interests overseas, deter our adversaries, and, when necessary, place themselves between danger and the rest of us. It is right that the first duty of any Government is the defence of our realm. It therefore follows that the first duty of Parliament towards those who discharge that responsibility is to ensure that they are treated with fairness, dignity and respect. That means understanding that military service is not simply another profession, but a vocation that places demands on individuals and their families that most of our fellow citizens will never be asked to bear. I begin with new clause 4. I have long believed that when an individual commits to service in the armed forces, the nation enters a contract with them that carries practical consequences. We ask our service personnel to accept postings away from home, to move their families at short notice, to spend long periods separated from loved ones, and, in some cases, to place themselves in danger on our behalf. When we speak of supporting the armed forces, we cannot confine our attention solely to those in uniform; we must also consider the spouses and children who support them. New clause 4, tabled by my hon. and gallant Friend the Member for Huntingdon (Ben Obese-Jecty), addresses a concern that many Members across this House have heard repeatedly from serving personnel and veterans alike: that the financial burden imposed on families seeking indefinite leave to remain after years of loyal service to this country is too much. There is a straightforward question before us. If an individual has given years of service to our nation, why should their family then face significant financial barriers simply to secure their future here? They have worn our uniform, accepted unlimited liability in defence of our national interests, and contributed directly to our security. In those circumstances it cannot be right, having honoured their commitment to our country, that we appear reluctant to honour our commitment to them. The armed forces covenant, as my right hon. and gallant Friend the Member for Rayleigh and Wickford (Mr Francois) mentioned, rests on the principle that those who serve should suffer no disadvantage as a result of that service. It is difficult to reconcile that principle with a situation in which a family that has supported a service member throughout years of deployments and postings, is then confronted with substantial costs in order to remain together in the country for which that service was given. New clause 4 is not a radical proposition; it is a relatively modest measure that simply recognises commitment and rewards service. Crucially, it sends a clear signal that Parliament values not only those who wear the uniform but the families who stand behind them. Over the past two decades, there has been a considerable concern about the extent to which human rights litigation has affected military operations overseas. Parliament has recognised those concerns in previous legislation relating to overseas operations. That issue is not a novel one, but part of a continuing debate about how best to reconcile operational effectiveness, accountability and fairness. The argument for new clauses 9 and 11 is, at its heart, a simple one. A soldier deployed on operations is not situated in the same circumstances as a civilian living in peacetime; the realities of combat are fundamentally different. Those of us who have had the privilege to spend time with serving personnel quickly come to appreciate that military operations are conducted in conditions of danger, ambiguity and enormous pressure. Decisions are often made in moments, not months. Commanders and soldiers do not enjoy the luxury of hindsight that is available to lawyers examining events years later from the cold comfort of a courtroom.

• 17 Jun 2026 · Steel Tariffs · Hansard source

  More

  The Minister is right to point to the uncertainty that businesses are facing, and my constituents and local businesses repeat that message to me regularly. The Minister has indicated that there may be a chance that some of the tariffs or the categorisations will be changed. Will he undertake to come to the House and make a statement as soon as that is announced?

• 15 Jun 2026 · Brain Cancer · Hansard source

  More

  I am very grateful to my hon. Friend for sharing Holly’s story, which sadly, is far too frequent. I remember from my time in clinical practice that those subtle signs were sadly sometimes missed. We need to do much more to ensure that our clinicians are aware of them so that they can make an early diagnosis. Of course, when those diagnoses arrive, it is inevitably devastating. It turns lives upside down in an instant. Parents are told that their child has a condition with few treatment options, husbands and wives are forced to confront an uncertain future and children become carers. Families who should be planning birthdays, holidays and life milestones instead find themselves navigating endless hospital corridors, scans and treatments. Behind every statistic is a person and behind every policy discussion is a family desperately hoping for more time. Today, I want to particularly recognise the courage of those families whose stories have been shared, often while living through the most unimaginable grief, so that others might one day have a better chance. I also want to pay tribute to the remarkable charities, researchers, clinicians and campaigners who have worked tirelessly to keep this issue on the national agenda: organisations such as the Brain Tumour Charity, Tessa Jowell Brain Cancer Mission, Brain Tumour Research, Cancer Research UK and countless others that have not only supported patients and families, but have driven forward research, awareness and innovation.

• 15 Jun 2026 · Brain Cancer · Hansard source

  More

  The hon. Gentleman is absolutely right. There are countless charities that have done a huge amount of work, and what they are doing is making a tangible difference to people’s lives. Sadly, brain tumours remain one of the most challenging forms of cancer. In many instances, outcomes are no better than when I worked as a doctor in neurosurgery almost a decade and a half ago. The less survivable cancers taskforce has highlighted that one-year survival rates for less survivable cancers, which include brain cancers, remain significantly lower than the average across all cancers. Despite advances in medicine, outcomes for many patients have not improved at the pace that we would all wish to see. That is why the concerns raised by the petitioners are so important. Quite rightly, the petition calls for greater investment in research, wider access to whole-genome sequencing and stronger support for innovative treatments. Those are priorities that cannot be ignored any longer. However, before I turn to those challenges, I want to take a moment to acknowledge the progress that has been made. The National Institute for Health and Care Research has established the brain tumour research consortium, which has brought together dozens of organisations to co-ordinate research and is backed by up to £25.5 million of investment. The recently enacted Rare Cancers Act 2026 represents another significant step forward, and I want to commend the hon. Member for Edinburgh South West (Dr Arthur) for his work in bringing that legislation on to the statute book. The establishment of the national speciality lead and a dedicated cancer registry service have the potential to improve co-ordination and data collection and strengthen research. The national cancer plan has recognised rare cancers as a priority area and committed to expanding successful models such as the Tessa Jowell Brain Cancer Mission. Those developments are of course all welcome. As His Majesty’s loyal Opposition, we supported the Rare Cancers Act throughout its passage through Parliament because we recognise that patients with rare cancers deserve the same urgency, focus and ambition as those with more common conditions. However, the reality is that legislation alone does not save lives; the real test is the effectiveness of its implementation. I would therefore be grateful if the Minister could update us on what progress has been made in establishing the new structures required under the Rare Cancers Act. In particular, has the national specialty lead been appointed? When will the rare cancer registry become fully operational? How will success be measured? Patients and families deserve to know when they will begin to see tangible benefits from the legislation that Parliament has passed. The petition also raised important questions about research participation and access to innovation. The Tessa Jowell Brain Cancer Mission highlighted that fewer than 5% of eligible adult brain tumour patients were able to access whole-genome sequencing because of limitations in tissue sampling and biobanking capacity, which is deeply concerning. Genome sequencing has enormous potential to improve the understanding of tumour biology, identify personalised treatment pathways and increase participation in clinical trials. However, opportunities remain unevenly distributed across the country. The Brain Tumour Charity has also highlighted significant variations in infrastructure and staffing across neuro-oncology centres.

• 15 Jun 2026 · Brain Cancer · Hansard source

  More

  The hon. Lady is absolutely right that when someone is facing a devastating crisis, but has to travel excessive distances to get the treatment they deserve, there is something wrong with the system. If we are serious about accelerating research, we must ensure that every patient has a fair opportunity to participate in it. That requires investment not only in laboratories and technology, but in a workforce that supports research and clinical innovation. What specific action are the Government taking to address those disparities and ensure that advances in research can benefit patients regardless of where they live? The petition also reflects a wider frustration felt by many families facing brain cancer. When conventional options are exhausted, patients understandably look to emerging treatments and clinical trials with hope. Such hope is entirely understandable, but at the same time we must maintain rigorous standards of safety and evidence. The challenge for us as policymakers is not choosing between innovation and safety; it is ensuring that innovation can be assessed, trialled and adopted as quickly as possible, when the evidence supports it. That is why clinical research capacity and trial recruitment matter so much, and it is why access to cutting-edge treatments must remain a key priority. On that point, the Government have committed to increase spending on branded medicines, and they have set out ambitious objectives for expanding participation in commercial clinical trials. Of course those ambitions are welcome, but they must be matched by delivery. The Office for Budget Responsibility has estimated that increasing spending on branded medicines will carry significant costs over the coming years, so can the Minister explain how the Government intend to fund those commitments? Patients need confidence that the announcements we hear today will be translated into treatments tomorrow. Similarly, while we welcome the publication of the national cancer plan earlier this year, questions remain about its implementation. The shadow Health and Social Care Secretary, my right hon. Friend the Member for Daventry (Stuart Andrew), supported the ambitions set out within the plan. However, he quite rightly called for clear, funded milestones, and those questions remain unanswered. When will the Government publish measurable targets for rare cancers, and how will progress be reported? For all the challenges that we have discussed today, it is important that we recognise the reasons for hope. Medical research continues to achieve what once seems impossible. Just a few years ago, diffuse intrinsic pontine glioma was regarded as one of the most devastating childhood brain cancers, with very few children surviving beyond two years. However, through participation in innovative clinical trials, a young boy from Belgium named Lucas Jemeljanova experienced something quite extraordinary. Having been diagnosed at six, he entered the trial and, over time, scans showed a shrinking tumour, which eventually disappeared altogether. Lucas is now 13, and he is considered cured. With every breakthrough that provides a scientific curiosity, the challenge before us as a Government, as an Opposition and as clinicians and researchers is to ensure that those breakthroughs happen more quickly and often, so that they can reach patients quicker. That is what the families behind this petition are seeking, and they deserve no less.

• 15 Jun 2026 · Brain Cancer · Hansard source

  More

  It is a pleasure to serve under your chairmanship this evening, Mrs Barker. I am grateful to the hon. Member for Colne Valley (Paul Davies) for opening this important debate, and to other right hon. and hon. Members for their contributions to it. I also pay tribute to Brain Cancer Justice and to all the people—over 109,000 in total—who signed this petition to ensure that we have had the opportunity to debate this important issue here today. At its heart, this debate has been about the patients, families and loved ones whose lives have been irreparably changed by a brain tumour diagnosis. For many families, of course, that diagnosis arrives suddenly, although too often it is also delayed.

• 15 Jun 2026 · Defence Investment Plan · Hansard source

  More

  Last week, the former Defence Secretary said that the Prime Minister was unable and the Chancellor unwilling to fund the resources needed to tackle the threats facing our nation. Does the Minister agree with that assessment, and if not, why not?

• 8 Jun 2026 · Topical Questions · Hansard source

  More

  I listened carefully to the Minister’s response to my hon. Friend the Member for Broadland and Fakenham (Jerome Mayhew), but the reality is that every day shopkeepers are facing abuse and threats and being stolen from. A direct consequence of the presumption in the Sentencing Act 2026 that those with a sentence of 12 months or less will not face prison is that there is no deterrent. Can the Minister genuinely say that our streets are safer as a result?

• 4 Jun 2026 · Jury Trials · Hansard source

  More

  4. What advice she has provided to the Government on the potential impact of restricting the right to jury trials on the rule of law.

• 4 Jun 2026 · Jury Trials · Hansard source

  More

  Imagine a scenario in which two individuals are both charged with the same offence and the factual matrix of each case is identical. However, the first defendant has a string of previous convictions, whereas the second has none. Under the Government’s proposal, the first defendant would be able to elect for a jury trial, depending on the length of the potential sentence, whereas the second would not. How does that align with the Solicitor General’s assessment of the rule of law?

• 1 Jun 2026 · Defence Readiness Legislation · Hansard source

  More

  6. Whether he plans to introduce a defence readiness Bill.

• 1 Jun 2026 · Defence Readiness Legislation · Hansard source

  More

  The Government’s constant refrain is that they are “working at pace”, but the reality is that our adversaries are doing exactly that. In an increasingly unstable world, the lack of a defence readiness Bill is a significant disadvantage. Will the Minister set out when the Bill will be published, and the specific date on which it will come before the House?

• 19 May 2026 · Topical Questions · Hansard source

  More

  T8. I think it is fair to say that the Government and I do not see eye to eye when it comes to the policy of curtailing trial by jury. However, if the Government are determined to go down that route, their own impact assessment sets out that a significant number of magistrates need to be recruited—the MOJ has put it at 7,000 over three years. In order for the Government’s own plan to work, will they commit not to change any of the rules around trial by jury until they have recruited those magistrates?

• 23 Apr 2026 · Business of the House · Hansard source

  More

  Phoenix shops are a blight on many of our high streets, including in my constituency of Solihull West and Shirley. Councillor Karen Grinsell, the leader of Solihull metropolitan borough council, recently brought forward a motion to have greater statutory powers to close down these stores. Will the Leader of the House provide Government time to debate this issue so that we can close these stores for good?

• 20 Apr 2026 · Security Vetting · Hansard source

  More

  Quis custodiet ipsos custodes? As the Prime Minister will know, that means “Who guards the guards themselves?” With that in mind, and on the subject of holding those in power to account, can he explain why he took almost a week to come to this House, when the public will have been expecting answers much sooner?

• 16 Apr 2026 · Armed Forces Bill (Sixth sitting) · Hansard source

  More

  It is a pleasure to serve under your chairmanship, Mr Efford. Before I start, I should probably put it on record that I am on the RARO—Regular Army Reserve of Officers—list as a former Regular Army officer. I joined my right hon. Friend the Member for Rayleigh and Wickford on the delegation to Ukraine, which was put together by UK Friends of Ukraine and during which we had some very interesting conversations, as he said, about the ability to mobilise reserve forces at a time of pressing threats. I want to speak very briefly—I am sure other Members will be pleased that my contribution will be brief—on amendments 20 to 24. I will start with amendments 20 and 21, with amendment 21 being consequential on amendment 20. These appear to be sensible technical amendments that would bring the Bill in line with the civilian world. In the light of the facts that the retirement age is likely to be pushed forward as people are living longer, that we need to have a more flexible and resilient reserve force, and that the nature of warfare has changed, with many more technical roles, it seems sensible to increase the age of liability to 67. On amendment 22, my right hon. Friend set out very clearly the growing threats. It is a daily occurrence for us in this place to be talking about the increasing and ongoing threats facing us across the world. In those circumstances, it seems wise to extend the duration of a recall order from 12 months to 18 months. That does not mean it would have to go up to the 18-month point, but it would provide more flex and resilience in the system. Amendment 23, again, reflects the realities of life. Many individuals who have served in uniform go into roles that are vital for our defence, albeit are no longer required still to wear the uniform of His Majesty. In those circumstances, to lose their skillset by automatically requiring them to be recalled from those reserved occupations seems counterproductive to the aims we should be seeking to achieve. Finally, amendment 24 recognises the reality of the situation we live in. We need more flexibility to respond with agility and speed to changing circumstances. Therefore, halving the notice period for recall from 180 days to 90 would seem a sensible and prudent approach. I promised Members that my contribution would be short this time, and I have delivered on that promise.

• 16 Apr 2026 · NHS Federated Data Platform · Hansard source

  More

  I was expecting a promotion there, Dame Siobhain. It is a pleasure to serve under your chairmanship. I congratulate the hon. Member for Newton Abbot (Martin Wrigley) on securing the debate. He has brought forward an issue that sits right at the centre of how we shape the future of our national health service: how we use data, who we trust with it and how we ensure that technology supports care rather than complicates it. The debate has been a thoughtful one, and in many respects it has been revealing. It has shown both the promise of the NHS federated data platform and the unease that still surrounds it. That tension really matters. I am grateful for the significant contributions we have heard from right hon. and hon. Members, with 13 coming from the Back Benches by my count. Let me start by setting out where I think there is common ground across the House. The NHS is under enormous pressure as demand is rising, complexity is increasing and waiting lists remain too high. Too often, clinicians are working without the full picture in front of them. Anyone who has spent time in the health service knows that this is not a system that lacks dedication. It is, however, a system that too often lacks coherence. Data is part of that problem as it is scattered, fragmented and difficult to use in a joined-up way. Records do not always reliably follow the patient, and information is duplicated, delayed or simply not available when it is needed most. The consequence of that is not just theoretical; it is time lost, inefficiencies and, at times, patients not getting the care they should when they should. The case for doing things better is a strong one; in fact, it is unavoidable. The FDP is one attempt to respond to that challenge. It seeks to bring together information in a way that allows the NHS to work more effectively, helping clinicians and supporting managers with the ultimate aim of improving care for patients. There are some early signs that this is beginning to deliver; waiting lists have been cleaned up, and some hospitals have reported better flow through theatres and wards. Those are practical improvements. As is so often the case in government, the easier question is whether something can work; the much harder question is whether it will be accepted. There are clearly concerns here. We have heard about reluctance in part of the workforce. I am not suggesting there is uniform opposition, but there is certainly hesitation and, in some cases, disengagement. We should be careful, however, not to exaggerate that. Big reforms in the NHS have always faced resistance, often at the start. This is not necessarily something new, and on its own it is not necessarily decisive. At the same time, however, it is not irrelevant; if the people expected to use this system do not have confidence in it, its impact will always be limited. Will the Minister say what is the assessment of staff engagement with the FDP and how the Government are ensuring that this is something done with the NHS, rather than done to it? In the end, that will make the real difference. The same issue arises with public trust. People are right to care about their medical data—it is sensitive, personal and deeply private. Once confidence is lost in this area, it is very difficult to rebuild it. There are important safeguards in place: the data remains under NHS control, the access is tightly regulated, and the provider does not own or use the data for its own purposes. The legal framework underpinning those safeguards is strong. Those are not minor points—they really matter. However, we also have to recognise something else. People are not just asking whether the system is safe today, but what it enables tomorrow. Could the data be combined in ways that reveal more than people expect? Could systems evolve in ways not originally intended? Could future Governments choose to use the capability in different ways? Those are not unreasonable questions; they are the natural questions people ask when large new systems are created. Again, I ask the Minister what more will be done to reassure the public about the limits of how NHS data can be used and whether he can set out clearly where parliamentary oversight comes in if the use of data is expanded in the future. Trust is not built by reassurance alone; it is built by clarity and restraint. A significant part of this debate has understandably focused on Palantir, and it is right that it has. Palantir is now a major supplier within the NHS data infrastructure as well as elsewhere across Government, and that raises legitimate questions about not just capability but dependence. For some the concern is political, while for others it is about principle. For many, though, it is something much more practical: what happens if we become too reliant on a single provider for something as critical as health data infrastructure? I think that is a fair question. However, we should also separate those questions from the broader argument about the company’s international work. In a global economy, companies will inevitably work with different Governments, and that alone is not a sufficient reason to exclude them from public contracts in the UK. The question of procurement design, competition and resilience, however, is a different matter.

• 16 Apr 2026 · NHS Federated Data Platform · Hansard source

  More

  If the hon. Gentleman will forgive me, I will not. I want the Minister to have sufficient time to respond to the multiple contributions there have been today. I ask the Minister the following questions. How are the Government ensuring that the NHS is not locked into a single supplier over the long term? What is the plan for maintaining genuine competition in this space? How easy would it be in practical terms to move to an alternative system if that was ever required? There is then the issue of resilience. Some have argued that the FDP creates a single point of failure, while others have argued that the current fragmented system is itself a weakness and that greater coherence improves security and oversight. Both arguments deserve to be taken seriously. But practical questions remain: how resilient is this system to cyber-attacks or technical failure? What safeguards are in place? What happens if something goes wrong at scale? The last matter I wish to address is that of governance. With the abolition of NHS England, there is now a question about where the responsibilities for the FDP properly sit. That matters because accountability cannot be diffuse. I take this opportunity to ask the Minister: who is responsible for the programme now, where does that accountability lie, and how will Parliament be able to scrutinise its performance going forward? Better use of data has a real role to play in NHS reform, and the FDP may well prove to be part of that answer. Success will depend on more than just delivery; it will depend on confidence within the system: confidence from clinicians that the system helps rather than hinders them, confidence from patients that their data is properly protected and confidence from the public that our decisions are transparent, proportionate and properly accountable. If those conditions are met, this reform can succeed. If they are not, even the best designed system will struggle. We, as His Majesty’s loyal Opposition, will support what improves care and welcome what works, but will continue to ask questions that ensure reform is done properly in a way that sustains public trust. I look forward to the Minister’s response.